Out-licensing: Altoprev (extended Release Lovastatin)

Latest: Watch here for details of new products and services.

About Us: Pharmalicensing - Partnering solutions for the life sciences
Our Products: Overview; Partnering Search; Company Profiling; Pay-per-Click New!; Deal Negotiation; PL Intelligence; Reports; Comparison
PL Intelligence: Overview; Industry news; Deals review; Press releases; Articles
Case Studies: See what others think about our service
Newsletter: Partnering update; Key reports; Subscribe
Quick Links: Profile now; Register now; Profiled companies; Featured events; Industry news; PR Newswire; Jobs
Contact Pharmalicensing: Send an email; Call us: +44 1904 520460; Request a callback
RSS Feeds: Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd

Out-licensing
View

Altoprev (extended release Lovastatin)

Altoprev (extended release Lovastatin) is a patented once-a-day treatment for high cholesterol

Mechanism of action

Triple lipid control: Significant reductions in LDL, Increases HDL and reduces Triglycerides

Full description

Altoprev Mission Statement

Altoprev is the ideal statin that provides complete lipid management for your everyday dyslipidemic patient.

Brand Positioning

Altoprev addresses the complete lipid management by offering LDL reductions, exceptional HDL increases and TG decreases along with a proven record of safety and tolerability.

Development status

Registered

Type of business relationship sought

We are interested in out-licensing Altoprev outside the USA. Current priority is finding a distributor for the United Kingdom.

Licensing contact

Mr Sanjay Razdan
Senior Manager - Business Development
Business Development

Contact directly

Company details

Sciele Pharma Inc

Sciele Pharma Inc. acquires, develops, and markets prescription medicines within cardiovascular, obstetrical and gynaecological, paediatric and gastroenterological disorders

View profile

Visit website

Related reports

Are you looking for reports related to this particular subject. Our Reports section is the best place to start.

A2 Adenosine Receptor Agonists

IMG-003 - ULTRASOUND - Ultrasonic Blood Volume Flow Rate Meter

IMG-001 - MAGNETIC RESONANCE -Sliding Thin Slab Acquisition of MRI Data for MRA- SLINKY

Method and Composition for Optimizing Left Ventricular Videointensity in Echocardiography

Related categories

Industry sector: Pharmaceutical
Therapeutic target: Cardiovascular; Cardiovascular / Cardiovascular disorder (other)

Clients in focus...

Get the Flash Player to see this rotator.

Press releases: Pharmalicensing current industry press releases.

Products:	Partnering Search	Pay-per-Click	Company Profiling	PL Intelligence	Reports	Comparision
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Services
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Press releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us